Application of chimeric antigen receptor T cell immunotherapy in relapsed/refractory non-Hodgkin lymphoma
-
Abstract: Lymphoma has drawn much attention as one of the most common malignant tumors in China over the past years.With the development of treatment methods including chemotherapy,radiotherapy,hematopoietic stem cell transplantation,molecular targeted drugs and immune agents in the clinical practice,the survival of lymphoma patients has been significantly improved.However,still almost 30% to 40% patients died finally with relapsed/refractory lymphoma.As one of the adoptive cell treatments,Chimeric antigen receptor T-cell (CAR-T) immunotherapy developed rapidly in the past two decades.The remarkable therapeutic efficacy of CAR-T in B-cell line leukemia as well as certain lymphoma subtypes provides potential for treating relapsed/refractory lymphoma.In this review,we will discuss the progress,adverse events,management strategy,limitation and clinical application prospects of CAR-T immunotherapy.
-
Key words:
- chimeric antigen receptor /
- relapsed/refractory lymphoma /
- immunotherapy
-
-
[1] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66:115-132.
[2] Hudecek M,Lupo-Stanghellini MT,Kosasih PL,et al.Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells[J].Clin Cancer Res,2013,19:3153-3164.
[3] Zhao Z,Condomines M,van der Stegen SJC,et al.Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells[J].Cancer Cell,2015,28:415-428.
[4] Milone MC,Fish JD,Carpenito C,et al.Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo[J].Mol Ther,2009,17:1453-1464.
[5] Kochenderfer JN,Wilson WH,Janik JE,et al.Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19[J].Blood,2010,116:4099-4102.
[6] Kochenderfer JN,Dudley ME,Feldman SA,et al.B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells[J].Blood,2012,119:2709-2720.
[7] Kochenderfer JN,Dudley ME,Kassim SH,et al.Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor[J].J Clin Oncol,2015,33:540-549.
[8] Neelapu SS,Locke FL,Bartlett NL,et al.Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma[J].N Engl J Med,2017,377:2531-2544.
[9] Schuster SJ,Svoboda J,Chong EA,et al.Chimeric antigen receptor T cells in refractory B-cell lymphomas[J].N Engl J Med,2017,377:2545-2554.
[10] Turtle CJ,Hanafi LA,Berger C,et al.Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+and CD4+CD19-specific chimeric antigen receptor-modified T cells[J].Sci Transl Med,2016,8:355ra116.
[11] Zhong XS,Matsushita M,Plotkin J,et al.Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+T cell-mediated tumor eradication[J].Mol Ther,2010,18:413-420.
[12] Ruella M,June CH.Chimeric antigen receptor T cells for B cell neoplasms:Choose the right CAR for you[J].Curr Hematol Malig Rep,2016,11:368-384.
[13] Budde LE,Berger C,Lin Y,et al.Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma[J].PLoS One,2013,8:e82742.
[14] Di Stasi A,Tey SK,Dotti G,et al.Inducible apoptosis as a safety switch for adoptive cell therapy[J].N Engl J Med,2011,365:1673-1683.
[15] Lee DW,Gardner R,Porter DL,et al.Current concepts in the diagnosis and management of cytokine release syndrome[J].Blood,2014,124:188-195.
[16] Bonifant CL,Jackson HJ,Brentjens RJ,et al.Toxicity and management in CAR T-cell therapy[J].Mol Ther Oncolytics,2016,3:16011.
[17] Grupp SA,Kalos M,Barrett D,et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J].N Engl J Med,2013,368:1509-1518.
[18] Brentjens RJ,Riviere I,Park JH,et al.Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias[J].Blood,2011,118:4817-4828.
[19] Neelapu SS,Tummala S,Kebriaei P,et al.Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J].Nat Rev Clin Oncol,2018,15:47-62.
[20] Makita S,Yoshimura K,Tobinai K.Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma[J].Cancer Sci,2017,108:1109-1118.
[21] Maude SL,Frey N,Shaw PA,et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J].N Engl J Med,2014,371:1507-1517.
[22] Kochenderfer JN,Somerville RPT,Lu T,et al.Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels[J].J Clin Oncol,2017,35:1803-1813.
[23] Lee DW,Kochenderfer JN,Stetler-Stevenson M,et al.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults:a phase 1 dose-escalation trial[J].Lancet,2015,385:517-528.
[24] Davila ML,Sauter C,Brentjens R.CD19-targeted T cells for hematologic malignancies:clinical experience to date[J].Cancer J,2015,21:470-474.
[25] Maude SL,Barrett D,Teachey DT,et al.Managing cytokine release syndrome associated with novel T cell-engaging therapies[J].Cancer J,2014,20:119-122.
[26] Hu Y,Sun J,Wu Z,et al.Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy[J].J Hematol Oncol,2016,9:70.
[27] June CH,O'Connor RS,Kawalekar OU,et al.CAR T cell immunotherapy for human cancer[J].Science,2018,359:1361-1365.
-
计量
- 文章访问数: 245
- PDF下载数: 178
- 施引文献: 0
下载: